From the Guidelines
A patient who previously had an A1C of 6.7 that improved to 5.8 with Mounjaro (tirzepatide) still has a diagnosis of diabetes. Diabetes is a chronic condition that doesn't disappear when blood glucose levels improve with treatment. The improvement in A1C from 6.7 to 5.8 indicates that the diabetes is well-controlled with medication, which is the goal of treatment. Mounjaro is a GLP-1/GIP receptor agonist that helps lower blood sugar by increasing insulin secretion when glucose levels are high, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite. Even though the current A1C of 5.8 is below the diagnostic threshold of 6.5%, removing the diagnosis would be inappropriate as the patient would likely return to diabetic levels if the medication were discontinued, as supported by the most recent guidelines from the American Diabetes Association 1. This is similar to how a patient with hypertension who achieves normal blood pressure with medication still has a diagnosis of hypertension. The patient should continue their medication as prescribed and maintain regular follow-ups with their healthcare provider to monitor their condition, following the recommendations for confirming the diagnosis of diabetes 2, 1. Key points to consider in the diagnosis and management of diabetes include:
- The use of A1C as a diagnostic criterion, with a threshold of 6.5% 3
- The importance of confirming the diagnosis with repeat testing, unless the diagnosis is clear on clinical grounds 2, 1
- The need for ongoing monitoring and management of the patient's condition, even if blood glucose levels are well-controlled with medication 1
From the Research
Diagnosis of Diabetes
- The diagnosis of diabetes is typically based on the results of blood tests, including the hemoglobin A1c (HbA1c) test 4, 5, 6.
- An HbA1c level of 6.5% or higher is generally considered diagnostic of diabetes 6.
- In the case of a patient who previously had an HbA1c of 6.7% and has improved to 5.8% with medication (Mounjaro), it is likely that the patient no longer meets the diagnostic criteria for diabetes 6, 7.
Impact of Medication on HbA1c Levels
- The use of medications such as Mounjaro (tirzepatide) has been shown to significantly reduce HbA1c levels in patients with type 2 diabetes 7.
- In clinical trials, tirzepatide has been associated with marked reductions in HbA1c levels, ranging from -1.87 to -2.59% 7.
- The improvement in HbA1c levels in the patient from 6.7% to 5.8% is consistent with the expected effects of tirzepatide therapy 7.
Clinical Implications
- The reduction in HbA1c levels to below 6.0% may be associated with a reduced risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes 6.
- However, the clinical implications of achieving an HbA1c level of 5.8% in this patient should be individualized and considered in the context of their overall health and medical history 4, 5, 8.